KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Cost of Revenue: 2011-2025

Historic Cost of Revenue for Novavax (NVAX) over the last 8 years, with Sep 2025 value amounting to $21.5 million.

  • Novavax's Cost of Revenue fell 64.54% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.6 million, marking a year-over-year decrease of 72.71%. This contributed to the annual value of $202.7 million for FY2024, which is 41.02% down from last year.
  • Per Novavax's latest filing, its Cost of Revenue stood at $21.5 million for Q3 2025, which was up 40.27% from $15.3 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Cost of Revenue ranged from a high of $434.6 million in Q3 2022 and a low of $14.1 million during Q1 2025.
  • Over the past 3 years, Novavax's median Cost of Revenue value was $46.2 million (recorded in 2024), while the average stood at $54.3 million.
  • Within the past 5 years, the most significant YoY rise in Novavax's Cost of Revenue was 124.19% (2023), while the steepest drop was 79.42% (2023).
  • Quarterly analysis of 4 years shows Novavax's Cost of Revenue stood at $181.8 million in 2022, then decreased by 14.74% to $155.0 million in 2023, then slumped by 76.34% to $36.7 million in 2024, then plummeted by 64.54% to $21.5 million in 2025.
  • Its Cost of Revenue was $21.5 million in Q3 2025, compared to $15.3 million in Q2 2025 and $14.1 million in Q1 2025.